Welcome to LookChem.com Sign In|Join Free

CAS

  • or
3-Amino-2-hydroxybenzoic acid methyl ester is a disubstituted benzoic acid derivative characterized by the presence of an amino and a hydroxyl group at the 3 and 2 positions, respectively. It is commonly used as a synthetic intermediate in the pharmaceutical industry due to its unique chemical properties and reactivity.

35748-34-6

Post Buying Request

35748-34-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

35748-34-6 Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-2-hydroxybenzoic acid methyl ester is used as a synthetic intermediate for the preparation of various pharmaceutical compounds, such as sphingosine kinase inhibitors. These inhibitors play a crucial role in the development of drugs targeting various diseases, including cancer and inflammatory disorders, by modulating the activity of sphingosine kinase enzymes.

Check Digit Verification of cas no

The CAS Registry Mumber 35748-34-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,7,4 and 8 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 35748-34:
(7*3)+(6*5)+(5*7)+(4*4)+(3*8)+(2*3)+(1*4)=136
136 % 10 = 6
So 35748-34-6 is a valid CAS Registry Number.
InChI:InChI=1/C8H9NO3/c1-12-8(11)5-3-2-4-6(9)7(5)10/h2-4,10H,9H2,1H3

35748-34-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H33035)  Methyl 3-aminosalicylate, 97%   

  • 35748-34-6

  • 1g

  • 1013.0CNY

  • Detail
  • Alfa Aesar

  • (H33035)  Methyl 3-aminosalicylate, 97%   

  • 35748-34-6

  • 5g

  • 4090.0CNY

  • Detail

35748-34-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl 3-amino-2-hydroxybenzoate

1.2 Other means of identification

Product number -
Other names 3-amino-2-hydroxy-benzoic acid methyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:35748-34-6 SDS

35748-34-6Relevant articles and documents

Substituted pyrazole compound, preparation method, pharmaceutical composition and applications thereof

-

Paragraph 0213-0217, (2020/03/12)

The invention discloses a substituted pyrazole compound represented by a formula I, and a preparation method, a pharmaceutical composition and applications thereof, wherein the compound has characteristics of good stability, excellent solubility, low cytotoxicity and remarkable neuroprotective effect, can effectively prevent and treat nerve cell injury, and is an ideal medicinal compound for preventing or treating cerebral stroke, cerebral embolism, cerebral stroke sequelae, cerebral stroke dyskinesia, mitochondrial encephalomyopathy and amyotrophic lateral sclerosis of spinal cord.

As neuroprotective agents of pharmaceutical compounds

-

Paragraph 0100; 0101; 0105-0107, (2019/06/26)

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

Benzo wicked zuozuo apperception compound and its preparation and use

-

Paragraph 0046-0048, (2017/10/27)

The invention provides a benzoxazole compound. The structure of the benzoxazole compound is shown in the formula (I), wherein R1, R2, R3 and R4 are hydrogen, C1-C5 alkyl, benzyl, aryl or hetero aryl. The preparation method of the benzoxazole compound is carried out according to the following reaction route. Compared with the prior art, the benzoxazole compound has the benefits that the Sortase A protease of bacteroid is used as a target spot, a similar structure of a Sortase A substrate is constructed through the action mechanism of the known Sortase A and the cell wall of a host cell, and new compounds with benzoxazole and mother nucleus are synthesized; the new compounds carry out the test screening of Sortase A activity inhibition so as to try to find candidate compounds for effectively inhibiting staphylococcus aureus infection.

Fe-Catalyzed Amination of (Hetero)Arenes with a Redox-Active Aminating Reagent under Mild Conditions

Liu, Jianzhong,Wu, Kai,Shen, Tao,Liang, Yujie,Zou, Miancheng,Zhu, Yuchao,Li, Xinwei,Li, Xinyao,Jiao, Ning

supporting information, p. 563 - 567 (2017/01/18)

A novel and efficient Fe-catalyzed direct C?H amination (NH2) of arenes is reported using a new redox-active aminating reagent. The reaction is simple, and can be performed under air, mild, and redox-neutral conditions. This protocol has a broad substrate scope and could be used in the late-stage modification of bioactive compounds. Mechanistic studies demonstrate that a radical pathway could be involved in this transformation.

COMPOUND HAVING ZNF143 INHIBITORY ACTIVITY AND USE THEREOF

-

Paragraph 0138, (2016/10/27)

PROBLEM TO BE SOLVED: To provide a compound having a ZNF143 inhibitory activity as well as to provide a ZNF143 inhibitory agent and pharmaceutical composition containing the same. SOLUTION: Provided is a compound represented by formula (I) or a salt thereof as well as a ZNF143 inhibitory agent containing the same and a pharmaceutical composition having the same as an active ingredient. A-B-C-D (I)[A is H, a methyl group, a naphthyl group, a phenyl group or a nitrogen-containing heterocyclic ring; B is as shown below, and C is an amide bond or a heteroaromatic ring containing N and O; D is a substituted/unsubstituted phenyl group or a monocyclic heteroaromatic ring containing N or S; and C and D are both fused heterocyclic ring or the like optionally having a substituent group.]. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT

Synthesis, biological evaluation and molecular docking of 2-phenyl-benzo[d]oxazole-7-carboxamide derivatives as potential Staphylococcus aureus Sortase A inhibitors

Zhang, Yong,Bao, Jian,Deng, Xin-Xian,He, Wan,Fan, Jia-Jun,Jiang, Fa-Qin,Fu, Lei

, p. 4081 - 4085 (2016/08/01)

A series of novel 2-phenyl-benzo[d]oxazole-7-carboxamide derivatives were designed, synthesized and evaluated for their in vitro inhibitory activities against Staphylococcus aureus Sortase A with known Sortase A inhibitor pHMB as positive compound (IC50?=?130?μM). Most compounds exhibited excellent inhibitory activity (IC50?=?19.8–184.2?μM). Structure–activity relationship studies demonstrated that substitution at 7-position and 2-position of benzoxazole had great influence on the activities. Specifically, the substituent at 7-position is indispensable for inhibitory activity. The molecular docking studies revealed the i-butyl amide group went towards the β6/β7 loop-β8 substructure of the protein and the benzoxazole core lied in a hydrophobic pocket composed of Ala118, Val166, Val168, Val169 and Ile182, shaping the whole molecule into a L-shape mode to be recognized by Sortase A.

ANTI-MALIGNANT TUMOR AGENT COMPOSITION

-

Paragraph 0116, (2016/01/25)

To provide a satisfactory anticancer agent composition suppressing the growth of cancer (malignant tumor) reliably and hardly causing side effects, the present invention is directed to an anticancer agent composition including the following agents as active ingredient; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.

Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists

Hansen, Martin,Jacobsen, Stine Engesgaard,Plunkett, Shane,Liebscher, Gudrun Eckhard,McCorvy, John D.,Br?uner-Osborne, Hans,Kristensen, Jesper Langgaard

supporting information, p. 3933 - 3937 (2015/01/30)

N-Benzyl substitution of phenethylamine 5-HT2A receptor agonists has dramatic effects on binding affinity, receptor selectivity and agonist activity. In this paper we examine how affinity for the 5-HT2A/2C receptors are influenced by N-benzyl substitution of 4-bromo-2,5-dimethoxyphenethylamine derivatives. Special attention is given to the 2′ and 3′-position of the N-benzyl as such compounds are known to be very potent. We found that substitutions in these positions are generally well tolerated. The 2′-position was further examined using a range of substituents to probe the hydrogen bonding requirements for optimal affinity and selectivity, and it was found that small changes in the ligands in this area had a profound effect on their affinities. Furthermore, two ligands that lack a 2′-benzyl substituent were also found to have high affinity contradicting previous held notions. Several high-affinity ligands were identified and assayed for functional activity at the 5-HT2A and 5-HT2C receptor, and they were generally found to be less efficacious agonists than previously reported N-benzyl phenethylamines.

Evaluation of the Synthetic Potential of an AHBA Knockout Mutant of the Rifamycin Producer Amycolatopsis mediterranei

Bu?yszko, Ilona,Dr?ger, Gerald,Klenge, Anja,Kirschning, Andreas

supporting information, p. 19231 - 19242 (2016/01/26)

Supplementing an AHBA(-) mutant strain of Amycolatopsis mediterranei, the rifamycin producer, with a series of benzoic acid derivatives yielded new tetraketides containing different phenyl groups. These mutasynthetic studies revealed unique reductive properties of A. mediterranei towards nitro- and azidoarenes, leading to the corresponding anilines. In selected cases, the yields of mutaproducts (fermentation products isolated after feeding bacteria with chemically prepared analogs of natural building blocks) obtained are in a range (up to 118 mg L-1) that renders them useful as chiral building blocks for further synthetic endeavors. The configuration of the stereogenic centers at C6 and C7 was determined to be 6R,7S for one representative tetraketide. Importantly, processing beyond the tetraketide stage is not always blocked when the formation of the bicyclic naphthalene precursor cannot occur. This was proven by formation of a bromo undecaketide, an observation that has implications regarding the evolutionary development of rifamycin biosynthesis.

Organoboron-based allylation approach to the total synthesis of the medium-ring dilactone (+)-antimycin A1b

Janetzko, John,Batey, Robert A.

, p. 7415 - 7424 (2014/10/15)

The stereoselective synthesis of (+)-antimycin A1b has been accomplished in 12 linear steps and 18% overall yield from (-)-ethyl lactate. A robust, scalable, and highly diastereoselective montmorillonite K10-promoted allylation reaction between

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 35748-34-6